Follicular lymphoma: open trials in China

52 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT07519772
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Beijing Cancer hospital (Site 1701), Beijing · Fujian Provincial Cancer Hospital.. (Site 1704), Fuzhou · Sun Yat-Sen University Cancer Center (Site 1712), Guangzhou · Fudan University Shanghai Cancer Center (Site 1711), Shanghai · Henan Cancer Hospital (Site 1702), Zhengzhou
Registry updated 2026-10-29
NCT07634471
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Trial Treatment · Phase 2/3 · Merck Sharp & Dohme LLC
Beijing Cancer hospital (Site 0501), Beijing · Fudan University Shanghai Cancer Center (Site 0504), Shanghai
Registry updated 2026-10-26
NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Trial Treatment · Phase 1/2 · BeOne Medicines
Beijing Chao-Yang Hospital, Capital Medical University, Beijing · Peking University Third Hospital, Beijing · The First Affiliated Hospital of Bengbu Medical University, Bengbu · The First Hospital of Jilin University, Changchun · The Second Xiangya Hospital of Central South University, Changsha · West China Hospital，Sichuan University, Chengdu · Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing · Affiliated Zhongshan Hospital of Dalian University, Dalian · Fujian Medical University Union Hospital, Fuzhou · Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou · Sun Yat-sen University Cancer Center, Guangzhou · The First Affiliated Hospital, Zhejiang University School of Medicine Branch Yuhang, Hangzhou · Anhui Provincial Hospital, Hefei · Shandong Cancer Hospital, Jinan · First Affiliated Hospital of Kunming Medical University, Kunming · Jiangxi Province Cancer Hospital, Nanchang · The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang · Jiangsu Province Hospital, Nanjing · The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning · Nanyang Central Hospital, Nanyang · Qingdao Central Hospital, Qingdao · Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai · The First Affiliated Hospital of Soochow University, Suzhou · Shanxi Provincial Cancer Hospital, Taiyuan · Institute of Hematology and Hospital of Blood Disease, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Union Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan · Xiangyang Central Hospital, Xiangyang · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-21
NCT06549595
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Trial Treatment · Phase 3 · AstraZeneca
Beijing · Changchun · Changsha · Chengdu · Chongqing · Fuzhou · Guangzhou · Hangzhou · Harbin · Hefei · Lanzhou · Nanchang · Nanjing · Nanning · Shandong · Shanghai · Shenyang · Shijiazhuang · Suzhou · Tianjin · Wenzhou · Wuhan · Xiamen · Xi'an · Zhengzhou
Registry updated 2026-10-21
NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Trial Treatment · Phase 1 · Pfizer
Hunan Cancer Hospital, Changsha · West China Hospital，Sichuan University, Chengdu · The First Affiliated Hospital of Guangzhou Medical University, Guangzhou · Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing · Zhongda Hospital Southeast University, Nanjing · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Registry updated 2026-10-15
NCT07424833
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Trial Treatment · Phase 1 · Ascentage Pharma Group Inc.
Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-15
NCT06526793
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Trial Treatment · Phase 2 · AstraZeneca
Chengdu · Guangzhou · Nanchang · Nanjing · Nantong · Shandong · Shanghai · Tianjin · Zhengzhou
Registry updated 2026-10-14
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Peking Union Medical College Hospital, Beijing · Nanfang Hospital, Southern Medical University, Guangzhou · Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Yichang Central Peoples Hospitaljiangnan Branch, Yichang · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-05
NCT06542250
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Trial Treatment · Phase 1/2 · AstraZeneca
Hangzhou · Shanghai
Registry updated 2026-09-30
NCT06830031
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Trial Treatment · Phase 1 · Shanghai Exuma Biotechnology Ltd.
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-09-11
NCT07788118
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Trial Treatment · Phase 1/2 · Second Affiliated Hospital, Zhejiang University, School of Medicine
The Second Affiliated Hospital,School of Medicine,Zhejiang University, Hangzhou, Zhejiang 310009, Hangzhou
Registry updated 2026-08-26
NCT07562022
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Trial Treatment · Phase 3 · Sinocelltech Ltd.
Beijing Cancer Hospital, Beijing
Registry updated 2026-08-13
NCT07609862
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Trial Treatment · Phase 1/2 · Guangzhou Lupeng Pharmaceutical Company LTD.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-07-30
NCT07719855
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
Trial Treatment · Phase 3 · Ruijin Hospital
Ruijin Hosiptal, Shanghai
Registry updated 2026-07-22
NCT06471738
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Trial Treatment · Phase 2 · Chinese PLA General Hospital
Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing
Registry updated 2026-07-20
NCT07555470
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-06-09
NCT07609446
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
Research · The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of Soochow University, Suzhou
Registry updated 2026-05-27
NCT06911502
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Trial Treatment · Phase 3 · Celgene
Beijing Cancer Hospital, Beijing · Beijing · Changchun · Changchun · Changsha · Fuzhou Fujian · Sun Yat-sen University Cancer Center, Guangzhou · Hangzhou · Harbin · Inner Mongolia Cancer Hospital, Hohhot · Shandong Cancer Hospital, Jinan · Kunming · Nanchang · Shanghai · Shanghai · Shenyang · Shenyang · Sichuan · Suzhou · Tianjin People's Hospital, Tianjin · Tianjin · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · Zhengzhou
Registry updated 2026-05-20
NCT07585747
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Qilu Hospital of Shandong Province, Jinan · The First Affiliated Hospital of NanChang University, Nanchang · Shenzhen Second People's Hospital, Shenzhen · Institute of Hematology & Blood Diseases Hospital, China, Tianjin · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-05-14
NCT07587840
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
Trial Treatment · Phase 2 · Liping Dou
Chinese PLA General Hospital, Beijing
Registry updated 2026-05-14
NCT07299149
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin · Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020, Tianjin
Registry updated 2026-05-13
NCT06852638
CD70-targeted immunoPET Imaging of Malignant Cancers
Trial Treatment · Phase 2 · RenJi Hospital
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai
Registry updated 2026-05-12
NCT07550855
Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma
Trial Treatment · Phase 2 · Sun Yat-sen University
Sun Yat-sen Universitiy Cancer Center, Guangzhou
Registry updated 2026-04-24
NCT04989621
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Trial Treatment · Phase 2 · Sun Yat-sen University
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,, Guangzhou · Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou · Guangdong General Hospital, Guangzhou
Registry updated 2026-04-23
NCT07548697
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Trial Treatment · Early phase 1 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2026-04-23

All Follicular lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error